INNOVACAP2024-07-012024-09-30 INNOVACAP2024-07-012024-09-30 INNOVACAP2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member INNOVACAP2024-07-012024-09-30in-bse-fin:OneOperatingExpenses02Member INNOVACAP2024-07-012024-09-30in-bse-fin:OneOperatingExpenses03Member INNOVACAP2024-07-012024-09-30in-bse-fin:OneOperatingExpenses04Member INNOVACAP2024-07-012024-09-30in-bse-fin:OneOperatingExpenses05Member INNOVACAP2024-07-012024-09-30in-bse-fin:OneOperatingExpenses06Member INNOVACAP2024-07-012024-09-30in-bse-fin:OneOperatingExpenses07Member INNOVACAP2024-07-012024-09-30in-bse-fin:OneOperatingExpenses08Member INNOVACAP2024-07-012024-09-30in-bse-fin:OneOperatingExpenses09Member INNOVACAP2024-07-012024-09-30in-bse-fin:OneOperatingExpenses10Member INNOVACAP2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member INNOVACAP2024-07-012024-09-30in-bse-fin:FourOperatingExpenses02Member INNOVACAP2024-07-012024-09-30in-bse-fin:FourOperatingExpenses03Member INNOVACAP2024-07-012024-09-30in-bse-fin:FourOperatingExpenses04Member INNOVACAP2024-07-012024-09-30in-bse-fin:FourOperatingExpenses05Member INNOVACAP2024-07-012024-09-30in-bse-fin:FourOperatingExpenses06Member INNOVACAP2024-07-012024-09-30in-bse-fin:FourOperatingExpenses07Member INNOVACAP2024-07-012024-09-30in-bse-fin:FourOperatingExpenses08Member INNOVACAP2024-07-012024-09-30in-bse-fin:FourOperatingExpenses09Member INNOVACAP2024-07-012024-09-30in-bse-fin:FourOperatingExpenses10Member INNOVACAP2024-09-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 544067 INNOVACAP NOTLISTED Innova Captab Limited Equity 2024-04-01 2025-03-31 2024-11-07 2024-10-29 INR Millions Half yearly 15:30:00 16:45:00 2024-11-07 2024-11-07 true Cash Flow Indirect Not applicable Single segment Drugs and Pharmaceutical products 2024-07-01 2024-09-30 Unaudited Consolidated 3182030000.00 22160000.00 3204190000.00 2050160000.00 142730000.00 -123070000.00 281740000.00 1490000.00 49910000.00 333140000.00 2736100000.00 468090000.00 0.00 468090000.00 94490000.00 23560000.00 118050000.00 0.00 350040000.00 0.00 0.00 0.00 0.00 350040000.00 160000.00 350200000.00 0.00 0.00 0.00 0.00 572250000.00 10 6.12 6.12 0.00 0.00 6.12 6.12 1. The above consolidated financial results of Innova Captab Limited ( the Company ) have been prepared in accordance with and comply in all material aspects with the Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 ( the act ) read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended. 2. The above consolidated financial results have been reviewed and recommended by Audit Committee at its meeting held on 07 November 2024. The Board of Directors at their meeting held on 07 November 2024 have approved the above results and taken them on record. The statutory auditors of the Company have expressed an unmodified review conclusion on the consolidated financial results for the quarter and half year ended 30 September 2024. 3. The Company has only one reportable segment i.e.“Drugs and pharmaceutical products” as per Ind-AS 108 Operating Segments specified under section 133 of the Companies Act, 2013. 4. The Company had completed its IPO of 12,723,214 equity shares of face value Rs. 10 each at an issue price of Rs. 448 per share (including a share premium of Rs. 438 per share) and as a result the equity shares of the Company were listed on NSE and BSE on 29 December 2023. The issue comprised of a fresh issue of 7,142,857 equity shares aggregating to Rs. 3,200.00 million and offer for sale of 5,580,357 equity shares by selling shareholders aggregating to Rs. 2,500.00 million. The Holding Company had estimated Rs. 478.39 million as IPO related expenses and allocated such expenses between the Holding Company (Rs. 272.79 million, out of this amount Rs. 263.17 million has been adjusted to the security premium account) and selling shareholders (Rs. 205.60 million) in proportion to the equity shares allotted to the public as fresh issue by the Holding Company and under offer for sale by selling shareholder respectively. Out of the total IPO proceeds the fund available in escrow account is Rs. 7.67 million for remitting funds for pending IPO related expenses (including Rs. 3.88 million is payable to selling shareholders on account of IPO expenses incurred on behalf of the Company). The Company had received an amount of Rs. 2,931.09 million (net of IPO expenses of Rs. 268.91 million) from proceeds out of fresh issue of equity shares. The utilisation of the net IPO proceeds is summarised below (Rs. in Million) Objects as per Prospectus Planned net proceeds as per prospectus Actual net proceeds Utilization upto 30-Sept-2024 Unutilized amount as on 30-Sept-2024 Repayment and / prepayment, in part or in full, of certain outstanding loans of subsidiary Company 1,444.00 1,444.00 1,444.00 - Investment in subsidiary for repayment and / or prepayment in part or full outstanding loan availed by the subsidiary 236.00 236.00 236.00 - Funding Company working capital requirements 720.00 720.00 720.00 - General corporate purpose 531.09 531.09 531.09 - Total Proceeds 2,931.09 2,931.09 2,931.09 - 5. The Group acquired Sharon Bio-Medicine Limited as on 30 June 2023. Accordingly, the statement of unaudited consolidated financial results includes the financial results of the Sharon Bio-Medicine Limited from 01 July 2023. 6. Books of accounts of the Company has been shifted to corporate office situated at plot number 320, Industrial area, Phase-I, Panchkula, 134113 vide Board Resolution dated 09 August 2024 Single segment 2024-04-01 2024-09-30 Unaudited Consolidated 6124730000.00 43400000.00 6168130000.00 3931340000.00 227390000.00 -97270000.00 530530000.00 2870000.00 98450000.00 613650000.00 5306960000.00 861170000.00 0.00 861170000.00 151450000.00 64910000.00 216360000.00 0.00 644810000.00 0.00 0.00 0.00 0.00 644810000.00 -770000.00 644040000.00 0.00 0.00 0.00 0.00 572250000.00 10 11.27 11.27 0.00 0.00 11.27 11.27 Commission on sales 26220000.00 Lab consumables 18910000.00 Miscellaneous expenses 100030000.00 Packing charges 22200000.00 Power and fuel 65060000.00 Rates, fees and taxes 11710000.00 Repairs and maintenance 24940000.00 Stores and spares consumed 26400000.00 Sub contracting charges 13010000.00 Travelling and conveyance 24660000.00 Commission on sales 44250000.00 Lab consumables 40800000.00 Miscellaneous expenses 166610000.00 Packing charges 42820000.00 Power and fuel 129460000.00 Rates, fees and taxes 20860000.00 Repairs and maintenance 45510000.00 Stores and spares consumed 50330000.00 Sub contracting charges 26970000.00 Travelling and conveyance 46040000.00 0.00 3433570000.00 4524390000.00 0.00 166940000.00 7920000.00 0.00 0.00 0.00 0.00 0.00 4330000.00 25860000.00 30190000.00 168280000.00 163580000.00 8494870000.00 1751920000.00 0.00 3291390000.00 33760000.00 147590000.00 10000000.00 67590000.00 3550330000.00 0.00 548350000.00 5850600000.00 0.00 0.00 14345470000.00 572250000.00 8380730000.00 8952980000.00 8952980000.00 2099940000.00 0.00 17490000.00 2117430000.00 96260000.00 81320000.00 0.00 0.00 2295010000.00 486660000.00 2051400000.00 344120000.00 2882180000.00 158870000.00 36750000.00 19680000.00 0.00 3097480000.00 0.00 0.00 5392490000.00 14345470000.00 The Company's operations relate to only one reportable segment viz Drugs and pharmaceutical products. Accordingly, no separate disclosure of segment information is required. 2870000.00 -318280000.00 -442240000.00 0.00 -24020000.00 2130000.00 0.00 -5600000.00 0.00 254960000.00 0.00 -17580000.00 0.00 98450000.00 0.00 9660000.00 0.00 15670000.00 0.00 630000.00 0.00 23810000.00 0.00 0.00 0.00 1980000.00 0.00 41310000.00 0.00 -403870000.00 457300000.00 0.00 0.00 0.00 141230000.00 0.00 316070000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1720000.00 1198840000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 35100000.00 0.00 602840000.00 0.00 -559180000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 168530000.00 0.00 0.00 5030000.00 0.00 3910000.00 0.00 0.00 159590000.00 -83520000.00 0.00 -83520000.00 117280000.00 33760000.00 -110000.00 -1360000.00 -270000.00 -590000.00 0.00 0.00